BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 14, 2025
Home » Topics » Science

Science
Science RSS Feed RSS

Prostate cancer cells

HSF1 inhibition directly targets treatment-resistant prostate cancer

Dec. 29, 2020
By John Fox
Scientists at Duke University School of Medicine in Durham, N.C., have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat-shock factor 1, which showed developmental promise against treatment-resistant prostate cancer and other cancers. The small molecule, Direct Targeted HSF1 InhiBitor (DTHIB), may also be a useful research tool for investigating the regulation and role of HSF1 in basic stress biology and in cancer.
Read More

BioWorld MedTech’s Oncology Extra for Dec. 29, 2020

Dec. 29, 2020
By Mark McCarty
Keeping you up to date on recent developments in oncology, including: Microscopic robots inch closer to clinical practicability; One thing often leads to another for cancer patients; PARP inhibitors under more scrutiny; New liposome may suppress false positives in FDG-PET.
Read More
Brain, illustrating pain/injury
Bench Press

Brain defense without swelling

Dec. 29, 2020
By Anette Breindl
BioWorld looks at translational medicine.
Read More
Condensate with individual protein molecules

Condensates offer broad vistas for Faze Medicines

Dec. 29, 2020
By Anette Breindl
Startup Faze Medicines Inc. launched in early December with a series A funding of $81 million, and an A list of investors, led by Third Rock Ventures – an indicator of the attention condensates are attracting from the biopharma industry. Faze CSO Rachel Meyers, though, named another indicator for condensates’ blue-ribbon status: rumors have it that the 7th edition of Molecular Biology of the Cell – a workhorse textbook for 30 years’ worth of students in the field – will be the first to include information on condensates.
Read More

BioWorld MedTech’s Cardiology Extra for Dec. 28, 2020

Dec. 28, 2020
By Liz Hollis
Keeping you up to date on recent developments in cardiology, including: Differences seen between the sexes in terms of stroke survival; Light used to control cardiac waves; 3D-printed blood vessels ID possible link between coronavirus, stroke.
Read More
Leukemia illustration

Nociceptive neurons shown to boost hematopoiesis

Dec. 28, 2020
By John Fox
A U.S. study has shown for the first time that enhancing signals from the nociceptive nervous system could provide new approaches to improve the collection of hematopoietic stem cells (HSCs) for treating cancers of the blood and bone marrow.
Read More
Clostridium difficile bacteria

CUHK develops rapid microrobotic diagnostic system for multiple pathogens

Dec. 23, 2020
By David Ho
HONG KONG – A research team at the Chinese University of Hong Kong (CUHK) has developed a fully automated, low-cost and rapid microrobotic diagnostic system that can be used with multiple pathogens, including COVID-19. The system works by integrating fluorescent microrobots with an external magnetic actuation system to detect pathogens in patient samples.
Read More

BioWorld MedTech’s Orthopedics Extra for Dec. 23, 2020

Dec. 23, 2020
By Holland Johnson
Keeping you up to date on recent developments in orthopedics, including: Remote monitoring leads to fourfold decline in returns to hospital after joint surgery; Researchers identify rare genetic bone disorder through massive sequencing methods; Orthogrid Systems says data support the use of its technology for orthopedic surgery; Exercise may protect bone health after weight loss surgery.
Read More
Prostate cancer cells

HSF1 inhibition directly targets treatment-resistant prostate cancer

Dec. 23, 2020
By John Fox
Scientists at Duke University School of Medicine in Durham, North Carolina, have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat-shock factor 1, which showed developmental promise against treatment-resistant prostate cancer and other cancers.
Read More
Bacteria in petri dishes

Inflammatory protein can distinguish between good and bad microbes

Dec. 23, 2020
By Subhasree Nag
Investigators at Leeds University have discovered that the proinflammatory cytokine IL-36gamma acts as a global early sensor of pathogenic invasion and discriminator of pathogenic and harmless microbes.
Read More
Previous 1 2 … 112 113 114 115 116 117 118 119 120 … 187 188 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 12, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of head with maze that is missing parts

    CTAD 2025: The challenges of combination therapies for dementia

    BioWorld Science
    At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
  • Brain and encephalography

    DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

    BioWorld
    Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing